The toxicity of antifolic acid drugs used in cancer therapy is also affected by the modification of genes encoding folic acid pathway protein, that is, the reduction of protein vector, folic acid vector, and the alteration of enzyme activities such as TS and MTHFR (Petrone et al. 2021; Song et al. 2021). Here, TYMS is linked to cancer.